Business Wire

Valuence Group Introduces Upgraded Market Price Chart Subscription Service

Share

Valuence Japan Inc. (Tokyo; Susumu Muguruma, representative director and president), a member of the Valuence Group (TOKYO:9270), announced on July 1, the launch of the official version of its winning bid market price chart, available by subscription. The official version of the service has been upgraded and comes with new, useful features. Star Buyers Auction is a luxury brand goods auction service operated by Valuence Japan.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210716005104/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Valuence Group Introduces Upgraded Market Price Chart Subscription Service (Graphic: Business Wire)

New Features and Upgrades Reflect Partner Input

The Valuence Japan-operated Star Buyers Auction is a pre-owned luxury branded goods B2B auction and the main sales channel of the Valuence Group. Since the launch of Star Buyers Auction, the service has continued to grow in scale, adding new categories and offering new services, including online global auctions. In February 2021, Valuence Japan introduced a beta version of a market price chart subscription service for use by partners around the world. This service displays global market prices (actual winning auction bids) for a variety of goods. The company received abundant and valuable feedback from its partners regarding bidding and consignment sales, at the same time attracting an increasing number of new subscribers.

Valuence Japan added new functions to the Star Buyers Auction market price chart subscription service, incorporating feedback from partners. The company released the official upgraded version of the service on July 1. At the same time, the company will continue to look at upgrading the service based on feedback, striving to create a global reuse platform serving as an indispensable part of the purchasing and selling markets.

Official Version and Upgrades

The official version of the market price chart service now allows users to enter multiple search terms, including brand and model names. This powerful upgrade reduces time spent in search for specific products. Users may also conduct searches by transaction date range, providing a narrower view of the vast amount of transaction data available. The search results screen now displays accessories, prices, and transaction dates in either ascending or descending order. Here, users will be able to sort through information, including accessories, price ranges, and other data for multiple products. Search results draw on the more than 25,000 items sold every auction, demonstrating the vast amount of valuable market data accumulated by Star Buyers Auction.

Valuence Japan is confident that the upgraded version of this service will deliver the type of market price information needed and used by the B2B auction partners.

Star Buyers Auction Overview

A luxury brand goods auction for reuse business dealers, launched in April 2013. In April 2020, auctions were migrated to a fully online format, listing a constantly stable stream of luxury items both in quantity and quality. Listings primarily focus on watches, bags, and brand jewelry procured by the Valuence Group. Auctions are held twice monthly. Market price chart subscription service is also available for 11,000 yen per month.

Official Site: https://biz.starbuyers-global-auction.com/en/

Youtube: https://youtu.be/efUtXrO9JkE

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Inquiries:
Aiko Kishi, Brand Communications Office, Valuence Holdings Inc.
Mail: media@valuence.inc

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

HiddenA line styled icon from Orion Icon Library.Eye